EU's CHMP says yes to Gilead's sofosbuvir
This article was originally published in Scrip
Executive Summary
Gilead's novel hepatitis C direct-acting antiviral against hepatitis C, sofosbuvir, is on its way to EU approval following a positive opinion from the CHMP as Sovaldi.